You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Patent: 10,023,841


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,023,841
Title:Methods and compositions for treating breast cancer with dendritic cell vaccines
Abstract: Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.
Inventor(s): Palucka; Anna Karolina (Avon, CT), Banchereau; Jacques F (Montclair, NJ), Roberts; Lee (Cordova, TN)
Assignee: Baylor Research Institute (Dallas, TX)
Application Number:14/719,968
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,023,841

Introduction

When analyzing a patent, such as United States Patent 10,023,841, it is crucial to delve into the specifics of the claims, the broader patent landscape, and the legal and procedural frameworks that govern patent law. This analysis will cover the key aspects of patent claims, the role of the Patent Trial and Appeal Board (PTAB), the evolving patent landscape, and critical considerations for patent holders and challengers.

Understanding Patent Claims

Patent claims are the heart of any patent application, as they define the scope of the invention for which protection is sought. The claims must meet several statutory requirements, including novelty, nonobviousness, and subject matter eligibility[1].

Novelty Requirement

For a patent to be granted, the claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[1].

Nonobviousness Requirement

The claimed invention must also be nonobvious, meaning it must be significantly different from existing knowledge and not obvious to a person having ordinary skill in the relevant field[1].

Subject Matter Eligibility

The claims must also be directed to eligible subject matter. This involves ensuring that the invention is not a law of nature, natural phenomenon, or abstract idea, unless the claims contain an "inventive concept" that transforms the nature of the claim[1].

The Role of the Patent Trial and Appeal Board (PTAB)

The PTAB, established by the Leahy-Smith America Invents Act (AIA) in 2011, plays a critical role in the patent landscape. It is a tribunal within the U.S. Patent and Trademark Office (USPTO) that hears administrative challenges to the validity of patents.

Inter Partes Review (IPR) and Post-Grant Review (PGR)

PTAB conducts Inter Partes Review (IPR) and Post-Grant Review (PGR) procedures, which allow anyone to challenge the validity of a patent before the USPTO. These procedures are often more advantageous than judicial proceedings due to their faster and less expensive nature, as well as the lower burden of proof required to invalidate patents[1].

Constitutional and Procedural Challenges

The PTAB has faced several constitutional and procedural challenges. For instance, the Supreme Court in Oil States Energy Services v. Greene’s Energy Group upheld the constitutionality of IPR, while in United States v. Arthrex Inc., the Court addressed the Appointments Clause issue by granting the Director of USPTO discretionary authority to review PTAB decisions[1].

The Evolving Patent Landscape

The patent landscape is dynamic and influenced by various factors, including technological advancements, legal precedents, and global competition.

Growth in Patent Applications

There has been a significant increase in patent applications over the years. For example, the number of patent applications filed at the USPTO grew from approximately 100,000 per year in the 1960s and 1970s to over 326,000 in 2001. This trend is driven by technological innovation and facilitated by technologies such as word processing and remote electronic database searching[2].

Cybersecurity Innovations

In the cybersecurity sector, the number of patent applications has accelerated, particularly in response to the rise in cyber attacks. The U.S. leads in cybersecurity patent filings, with over 1,087 patents filed since 2000. Other countries, such as China and those filing under the Patent Cooperation Treaty (PCT), also contribute significantly to this area[3].

Critical Considerations for Patent Holders and Challengers

Quality of Patents

The quality of patents is a critical issue. The USPTO has been working to define and improve patent quality, with measures such as statutory compliance rates for various sections of the patent code. However, critics argue that the PTAB has made it too easy to challenge patents, potentially stifling innovation and discouraging investments in patent-intensive industries[1][4].

Automated Patent Analysis

Given the increasing complexity and volume of patent claims, automated systems have been developed to facilitate the review and analysis of patent claims. For instance, the Patent Matrix software automates the import, parsing, and hierarchical arrangement of patent claims, making it easier to review and manage large numbers of claims[2].

International Competition

The patent landscape is also shaped by international competition. Countries like the U.S., China, and those filing under the PCT are key players. China, despite its high volume of patent applications, has faced criticism for the quality of its patents and has implemented stricter regulations to improve this aspect[3].

Case Studies and Legal Precedents

Electric Power Group, LLC v. Alstom S.A.

This case highlights the challenges in determining subject matter eligibility under 35 U.S.C. § 101. The court's decision emphasizes the importance of ensuring that patent claims are not directed to abstract ideas or laws of nature without an inventive concept[5].

Impact on Innovation and Litigation

Reducing Litigation Costs

The creation of PTAB was intended to improve patent quality and reduce unwarranted litigation costs. However, critics argue that PTAB's processes have created uncertainty in patent rights, potentially discouraging innovation and investment in early-stage companies[1].

Patent Trolls

PTAB is also seen as a mechanism to reduce litigation by so-called "patent trolls," entities that do not manufacture or sell the patented products but use patents primarily for litigation. By weeding out poor-quality patents, PTAB aims to mitigate this issue[1].

Key Takeaways

  • Patent Claims: Must meet novelty, nonobviousness, and subject matter eligibility requirements.
  • PTAB: Plays a crucial role in administrative challenges to patent validity through IPR and PGR.
  • Evolving Landscape: Influenced by technological advancements, legal precedents, and global competition.
  • Quality and Automation: Efforts to improve patent quality and automate claim analysis are ongoing.
  • International Competition: Key players include the U.S., China, and PCT filings.
  • Legal Precedents: Cases like Electric Power Group, LLC v. Alstom S.A. highlight the importance of subject matter eligibility.

FAQs

Q: What is the role of the Patent Trial and Appeal Board (PTAB) in the U.S. patent system? A: PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents through Inter Partes Review (IPR) and Post-Grant Review (PGR) procedures.

Q: How has the number of patent applications changed over the years? A: The number of patent applications has significantly increased, from approximately 100,000 per year in the 1960s and 1970s to over 326,000 in 2001, driven by technological innovation and facilitated by advanced technologies.

Q: Which countries lead in cybersecurity patent filings? A: The U.S. leads in cybersecurity patent filings, followed by international PCT filings and China.

Q: What are the main criticisms of PTAB? A: Critics argue that PTAB has made it too easy to challenge patents, creating uncertainty in patent rights, stifling innovation, and discouraging investments in patent-intensive industries.

Q: How does automated patent analysis help in managing patent claims? A: Automated systems like the Patent Matrix software facilitate the review and analysis of patent claims by automating the import, parsing, and hierarchical arrangement of claims, making it easier to manage large numbers of claims.

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Google Patents, "US20110138338A1 - Patent Claims Analysis System and Method."
  3. IS Decisions, "Cybersecurity Innovations And The Patent Landscape," November 21, 2023.
  4. Government Accountability Office, "Intellectual Property: Patent Office Should Define Quality, Reassess Processes," June 30, 2016.
  5. United States Court of Appeals for the Federal Circuit, "Electric Power Group, LLC v. Alstom S.A.," August 1, 2016.

More… ↓

⤷  Subscribe

Details for Patent 10,023,841

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 November 14, 2001 ⤷  Subscribe 2034-05-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.